1. Show article details.

    BRIEF-Caladrius Biosciences To Present On CLBS119 For COVID-19 Induced Lung Damage

    Reuters – 8:16 AM ET 06/02/2020

    Caladrius Biosciences Inc (CLBS): * CALADRIUS BIOSCIENCES TO PRESENT ON CLBS119 FOR COVID-19 INDUCED LUNG DAMAGE AT THE BIONJ COVID-19 RAPID FIRE RESEARCH SHOWCASE Source text for Eikon: Further company coverage:

  2. Show article details.

    Caladrius Biosciences to Present on CLBS119 for COVID-19 Induced Lung Damage at the BioNJ COVID-19 Rapid Fire Research Showcase

    GlobeNewswire – 8:05 AM ET 06/02/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the company has been selected to present at the BioNJ COVID-19 Rapid Fire Research Showcase on Friday, June 5, 2020. For more information on BioNJ’s COVID-19 Rapid Fire Research Showcase, please click here.

  3. Show article details.

    Caladrius Biosciences Closes $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    GlobeNewswire – 1:20 PM ET 05/28/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,084,850 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.0625 per share, in a registered...

  4. Show article details.

    Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    GlobeNewswire – 8:00 AM ET 05/26/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,084,850 shares of its common stock, at a purchase price of $2.0625 per...

  5. Show article details.

    Caladrius Biosciences Reports Positive Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

    GlobeNewswire – 3:42 PM ET 05/14/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, along with researchers from Cedars-Sinai, Mayo Clinic and The Christ Hospital, today presented full data results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angio...

  6. Show article details.

    Caladrius Biosciences Provides Corporate Update and Reports 2020 First Quarter Financial Results

    GlobeNewswire – 4:05 PM ET 05/07/2020

    Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringing current cash to ~$34 million Conference call begins today at 4:30 p.m. Eastern time BASKING RIDGE, N.J., May 07, 2020 -- Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the deve...

  7. Show article details.

    BRIEF-Caladrius Biosciences Announces Presentation Of Full Results For CLBS16 From The Escape-CMD Trial At SCAI 2020 Scientific Sessions

    Reuters – 8:43 AM ET 05/06/2020

    Caladrius Biosciences Inc (CLBS): * CALADRIUS BIOSCIENCES ANNOUNCES PRESENTATION OF FULL RESULTS FOR CLBS16 FROM THE ESCAPE-CMD TRIAL AT SCAI 2020 SCIENTIFIC SESSIONS Source text for Eikon: Further company coverage:

  8. Show article details.

    Caladrius Biosciences Announces Presentation of Full Results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions

    GlobeNewswire – 8:30 AM ET 05/06/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced it will present full data results from the ESCaPE-CMD trial of Caladrius’s autologous CD34+ cell therapy, CLBS16, at the Society for Cardiovascular Angiography and Interventions 2020 Scientific Sessions Virtual Confe...

  9. Show article details.

    Caladrius Biosciences to Host First Quarter 2020 Financial Results Conference Call on Thursday, May 7, 2020

    GlobeNewswire – 8:30 AM ET 04/30/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it will report financial results for the three months ended March 31, 2020 after the close of the U.S. financial markets on Thursday, May 7, 2020.

  10. Show article details.

    Caladrius Biosciences Closes $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    GlobeNewswire – 3:16 PM ET 04/27/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease, today announced that it has closed on its previously announced sale of an aggregate of 2,162,166 shares of its common stock to several institutional and accredited investors, at a purchase price of $2.3125 per share, in a registered...

  11. Show article details.

    BRIEF-Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

    Reuters – 2:05 PM ET 04/23/2020

    Caladrius Biosciences Inc (CLBS): * CALADRIUS BIOSCIENCES ANNOUNCES $5.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES. * Caladrius Biosciences Inc (CLBS) - AGREEMENTS FOR ISSUANCE AND SALE OF 2.2 MILLION SHARES OF COMMON STOCK AT $2.3125 PER SHARE.

  12. Show article details.

    Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

    GlobeNewswire – 2:00 PM ET 04/23/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardiovascular disease, today announced that it has entered into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 2,162,166 shares of its common stock, at a purchase price...

  13. Show article details.

    Caladrius Biosciences Plans to Assess its CLBS119 Cell Therapy for Repair of COVID-19 Induced Lung Damage

    GlobeNewswire – 8:55 AM ET 04/23/2020

    Caladrius Biosciences, Inc. (CLBS), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease today announced that the U.S. Food and Drug Administration has authorized its investigational new drug application for the study of CLBS119, a CD34+ cell therapy for repair of COVID-19 induced lung damage.

  14. Show article details.

    Caladrius Biosciences to Receive $10.9 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

    GlobeNewswire – 8:00 AM ET 04/22/2020

    Caladrius Biosciences, Inc. (CLBS), today announced that it has finalized an agreement to sell $10.9 million in New Jersey net operating losses to a qualifying and approved buyer pursuant to the New Jersey Economic Development Authority’s Technology Business Tax Certificate Transfer Program.

  15. Show article details.

    Caladrius Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update

    GlobeNewswire – 4:05 PM ET 03/05/2020

    CLBS16 ESCaPE-CMD data presented at American Heart Association 2019 Scientific Sessions demonstrated highly statistically significant improvement in coronary flow reserve and angina symptoms CLBS12 registration eligible trial in Japan targeted to complete enrollment in 1H2020; Data to date continues to corroborate previously published positive results CLBS14 is poised to commence a single confi...

  16. Show article details.

    Caladrius Biosciences to Host Fourth Quarter and Full Year 2019 Financial Results Conference Call on Thursday, March 5, 2020 at 4:30 p.m. Eastern Time

    GlobeNewswire – 8:30 AM ET 02/27/2020

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, today announced that it will report financial results for the three and twelve months ended December 31, 2019 after the close of the U.S. financial markets on Thursday, March 5, 2020.

  17. Show article details.

    Caladrius Biosciences to Participate at Upcoming February Conferences

    GlobeNewswire – 8:30 AM ET 02/03/2020

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that David J. Mazzo, PhD, President and Chief Executive Officer of the Caladrius, will present a company overview at the following conferences in February: LSX World Congress 2020 2020 BIO CEO & I...

  18. Show article details.

    Caladrius Biosciences to Participate at Upcoming January Conferences

    GlobeNewswire – 4:05 PM ET 01/07/2020

    Caladrius Biosciences, Inc. (CLBS), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the Company will present at the following conferences in January: The 2020 Biotech Showcase World Stem Cell Summit 2020 About Caladrius BiosciencesCaladrius is a late-stage therapeutics devel...

Page:

Today's and Upcoming Events

  • Aug
    06

    CLBS to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • May
    07

    CLBS announced Q1 earnings.

Data provided by Thomson Reuters © 2020

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.